- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07941843
Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer (LF-FOLFOX)
The Probability of a Protective Effect of Lactoferrin on FOLFOX-Related Toxicities in Colorectal Cancer
This randomized controlled clinical trial aims to investigate the potential protective effects of oral lactoferrin supplementation against chemotherapy-related toxicities in patients with colorectal cancer receiving the FOLFOX regimen.
A total of 44 eligible adult patients will be randomly allocated into two parallel groups (22 patients per group). The control group will receive standard FOLFOX chemotherapy, while the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin (Pravotin) at a dose of 100 mg twice daily, starting from the first chemotherapy cycle and continuing throughout the planned chemotherapy course.
The study will evaluate peripheral neuropathy, gastrointestinal and hematological toxicities, oxidative stress and neuroprotective biomarkers.
연구 개요
상태
상세 설명
Colorectal cancer is commonly treated with oxaliplatin-based chemotherapy regimens such as FOLFOX, which combines oxaliplatin, 5-fluorouracil, and leucovorin. Despite its therapeutic effectiveness, FOLFOX is associated with peripheral neuropathy, gastrointestinal toxicity, hematological abnormalities, and impaired quality of life.
Lactoferrin is an iron-binding glycoprotein with antioxidant, anti-inflammatory, immunomodulatory, and potential neuroprotective properties. These biological activities may help mitigate chemotherapy-induced toxicities.
This study will investigate the potential protective effects of lactoferrin supplementation in 44 patients with histologically confirmed colorectal cancer who are scheduled to receive at least six cycles of FOLFOX chemotherapy at Damanhour Oncology Center.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either standard FOLFOX chemotherapy alone or standard FOLFOX chemotherapy combined with oral lactoferrin 100 mg twice daily.
Participants will undergo clinical evaluations, laboratory monitoring, and assessment of chemotherapy-related adverse events. Laboratory investigations will include complete blood count, kidney and liver function tests, and serum biomarkers including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and malondialdehyde (MDA).
Clinical assessments and laboratory investigations will be conducted during chemotherapy, with final assessments at the completion of the planned chemotherapy course.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Toka M El-Banna, Clinical pharmacy TA
- 전화번호: 00201018546392
- 이메일: tokaelbanna@gmail.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adult patients aged 18 years or older with histologically confirmed colorectal cancer.
- Patients scheduled to receive at least six cycles of FOLFOX chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Exclusion Criteria:
- Pre-existing peripheral neuropathy of grade 1 or higher.
- Hereditary neuromuscular disorders.
- Advanced liver disease, defined as liver enzymes greater than three times the upper limit of normal or established cirrhosis.
- Chronic kidney disease with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Standard FOLFOX Chemotherapy
Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. |
|
실험적: FOLFOX Plus Lactoferrin
Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. Oral lactoferrin supplementation (Lactomash), administered at a dose of 100 mg twice daily (total daily dose: 200 mg), starting from the first FOLFOX chemotherapy cycle and continuing throughout the planned chemotherapy course. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Oxaliplatin-Induced Peripheral Neuropathy
기간: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Proportion of participants developing peripheral neuropathy during FOLFOX chemotherapy, assessed and graded according to biomarkers. |
From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- - Macciò A, et al. The Oncologist. 2010
- Lesser GJ, Irby MB, Taylor RC, Snavely A, Case D, Wang A, Dietrich A, Duncan S. Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy. Support Care Cancer. 2022 Mar;30(3):2017-2025. doi: 10.1007/s00520-021-06609-8. Epub 2021 Oct 13.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- LF-FOLFOX-CRC-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data (IPD) will not be shared.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .